Skip to content

Prepaid expenses at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s prepaid expenses?
Citius Oncology, Inc. (CTOR) reported prepaid expenses of $3.05M in Q1 2026.
How has Citius Oncology, Inc.'s prepaid expenses changed year-over-year?
Citius Oncology, Inc.'s prepaid expenses increased by 13.1% year-over-year, from $2.7M to $3.05M.
What is the long-term trend for Citius Oncology, Inc.'s prepaid expenses?
Over 2 years (2023 to 2025), Citius Oncology, Inc.'s prepaid expenses has grown at a -58.5% compound annual growth rate (CAGR), from $7.73M to $1.33M.